Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
News|Videos|June 8, 2018
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
Related to this article
A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5